<DOC>
	<DOCNO>NCT02296463</DOCNO>
	<brief_summary>This randomize , observer-blind , irrelevant comparator-controlled trial male female subject ≥24 month age &lt; 72 month age . Subjects without symptomatic chronic cardiopulmonary disease , include recurrent wheezing . Subjects screen seropositivity RSV qualify serum microneutralization ( MN ) assay exclude titer either RSV/A RSV/B &lt; 1:16 ( 4 log2 ) . Treatments comprise IM dose saline placebo RSV F vaccine Day 0 IM dose RSV F vaccine license hepatitis A vaccine Day 28 . Hepatitis A vaccine ( one group placebo ) use maintain study blind ; subject receive complete course hepatitis A vaccine study benefit .</brief_summary>
	<brief_title>A Phase I Randomized , Observer-Blinded , Dose-Ranging Study Healthy Subjects 24 &lt; 72 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female , ≥24 month age &lt; 72 month age , without know chronic cardiopulmonary disease include especially persistent frequently recurrent wheezing . 2 . Free illness believe increase risk associate influenza respiratory viral infection , include : diabetes mellitus , congenital acquire blood dyscrasia , renal hepatic dysfunction , morbid obesity . 3 . Parent ( ) /guardian ( ) willing able give inform consent prior study enrollment , assert ability comply study requirement . 4 . Parent ( ) /guardian ( ) and/or designate child care provider must continuous capacity telephone communication study site . 1 . Serum MN titer RSV/A RSV/B &lt; 1:16 ( 4 log2 ) . 2 . Toxicity grade ≥2 safety laboratory parameter . 3 . Participation research involve investigational product ( drug/biologic/device ) within 45 day plan date first vaccination plan participation time study . 4 . History serious reaction prior vaccination , include GuillainBarré Syndrome within six week follow previous influenza vaccination . 5 . Receipt vaccine ( influenza vaccine specify protocol ) four week precede first study vaccination and/or plan receipt license vaccine ( hepatitis A vaccine specify protocol ) time prior Study Day 56 . 6 . Receipt RSV vaccine time . 7 . Any known suspected immunosuppressive condition , acquire congenital , determined medical history and/or physical examination . 8 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥1 mg/kg prednisone per day equivalent . The use topical glucocorticoid minor cutaneous symptom permit , use nasal inhale glucocorticoid exclusionary ( potential relate diagnosis rather immunosuppression ) . 9 . Administration immunoglobulins and/or blood product within three month precede administration study vaccine study . 10 . Acute disease time enrollment ( define presence moderate severe illness without fever oral temperature &gt; 38.0°C planned day vaccine administration ) . 11 . Known disturbance coagulation . 12 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include social , neurologic , psychiatric condition subject parent ( ) /guardian ( ) deem likely impair quality safety reporting ) .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>72 Months</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>